2024
Mechanistically based blood proteomic markers in the TGF-β pathway stratify risk of hepatocellular cancer in patients with cirrhosis.
Xiang X, Bhowmick K, Shetty K, Ohshiro K, Yang X, Wong L, Yu H, Latham P, Satapathy S, Brennan C, Dima R, Chambwe N, Sharifova G, Cacaj F, John S, Crawford J, Huang H, Dasarathy S, Krainer A, He A, Amdur R, Mishra L. Mechanistically based blood proteomic markers in the TGF-β pathway stratify risk of hepatocellular cancer in patients with cirrhosis. Genes & Cancer 2024, 15: 1-14. PMID: 38323119, PMCID: PMC10843195, DOI: 10.18632/genesandcancer.234.Peer-Reviewed Original ResearchHepatocellular carcinomaPyruvate kinase M2TGF-bPresence of hepatocellular carcinomaEarly detection of HCCRisk of hepatocellular cancerDetection of hepatocellular carcinomaAdvanced incurable stageRisk-stratifying biomarkersTGF-B pathwayAssociated with hepatocellular carcinomaProteomic markersEarly detectionBiologically relevant markersIncurable stageBlood-based biomarkersHepatocellular cancerRisk stratificationStratify riskNon-HCCClinical variablesBlood levelsLiver diseaseAnimal modelsBiological role
2023
Nonalcoholic liver disease: Epidemiology, risk factors, natural history, and management strategies
Agyapong G, Dashti F, Banini B. Nonalcoholic liver disease: Epidemiology, risk factors, natural history, and management strategies. Annals Of The New York Academy Of Sciences 2023, 1526: 16-29. PMID: 37400359, PMCID: PMC10524684, DOI: 10.1111/nyas.15012.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNonalcoholic fatty liver diseaseNonalcoholic fatty liverLiver diseaseRisk factorsCommon chronic liver diseaseEnd-stage liver diseaseNatural historyNAFLD risk factorsChronic liver diseaseFatty liver diseaseCurrent management strategiesClinicopathologic spectrumLiver transplantationNonalcoholic steatohepatitisProgressive fibrosisFatty liverHepatocellular cancerLeading indicationDiseaseUnited StatesManagement strategiesCirrhosisSteatohepatitisTransplantationFibrosis
2022
692 Circulating tumor DNA analysis of advanced hepatocellular cancer (HCC) patients treated with neoantigen targeted personalized cancer DNA vaccine (GNOS-PV02) in combination with plasmid IL-12 (pIL12) and anti-PD1 (pembrolizumab)
Perales R, Perales-Puchalt A, Bartha G, Northcott J, Chen R, Lyle J, Norton D, Cooch N, Gane E, Yarchoan M, Marron T, Rochestie S, Peters J, Csiki I, Yan J, Sardesai N. 692 Circulating tumor DNA analysis of advanced hepatocellular cancer (HCC) patients treated with neoantigen targeted personalized cancer DNA vaccine (GNOS-PV02) in combination with plasmid IL-12 (pIL12) and anti-PD1 (pembrolizumab). 2022, a723-a723. DOI: 10.1136/jitc-2022-sitc2022.0692.Peer-Reviewed Original Research
2021
Apobec1 complementation factor overexpression promotes hepatic steatosis, fibrosis and hepatocellular cancer
Blanc V, Riordan JD, Soleymanjahi S, Nadeau J, Nalbantoglu I, Xie Y, Molitor EA, Madison BB, Brunt EM, Mills JC, Rubin DC, Ng I, Ha Y, Roberts LR, Davidson NO. Apobec1 complementation factor overexpression promotes hepatic steatosis, fibrosis and hepatocellular cancer. Journal Of Clinical Investigation 2021, 131 PMID: 33445170, PMCID: PMC7773377, DOI: 10.1172/jci138699.Peer-Reviewed Original ResearchConceptsHuman hepatocellular cancerHigh-fructose dietHepatocellular cancerNonalcoholic fatty liver diseaseFatty liver diseaseExpression of mRNALipogenic gene expressionSpontaneous fibrosisAdvanced fibrosisLiver diseaseLiver functionHepatic steatosisInflammatory pathwaysInflammatory responseFed chowLong-term effectsTissue microarrayHepatic proliferationMRNA expressionFactor overexpressionReduced survivalFibrosisOxidative stressExtracellular matrix organizationSteatosis
2017
Current and future pharmacologic treatment of nonalcoholic steatohepatitis
Banini BA, Sanyal AJ. Current and future pharmacologic treatment of nonalcoholic steatohepatitis. Current Opinion In Gastroenterology 2017, 33: 134-141. PMID: 28346237, PMCID: PMC5491795, DOI: 10.1097/mog.0000000000000356.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNonalcoholic fatty liver diseaseEnd-stage liver diseaseNonalcoholic steatohepatitisLiver diseaseTrend of NAFLDChemokine receptor type 2Future pharmacologic treatmentsCornerstone of therapyStage liver diseaseFatty liver diseasePeroxisome proliferator activator receptorProgression of fibrosisAnti-inflammatory agentsDietary caloric restrictionGlucagon-like peptide 1 pathwayReceptor type 2Liver histologyMetabolic endotoxemiaPharmacologic treatmentTherapeutic optionsHepatocellular cancerAntifibrotic agentsIntestinal microbiomeAggressive formPharmacologic target
2016
A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer
Asgharpour A, Cazanave SC, Pacana T, Seneshaw M, Vincent R, Banini BA, Kumar DP, Daita K, Min HK, Mirshahi F, Bedossa P, Sun X, Hoshida Y, Koduru SV, Contaifer D, Warncke UO, Wijesinghe DS, Sanyal AJ. A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer. Journal Of Hepatology 2016, 65: 579-588. PMID: 27261415, PMCID: PMC5012902, DOI: 10.1016/j.jhep.2016.05.005.Peer-Reviewed Original ResearchConceptsNon-alcoholic steatohepatitisNon-alcoholic fatty liver diseaseDiet-induced animal modelsProgressive non-alcoholic steatohepatitisHuman non-alcoholic steatohepatitisFatty liver diseaseHepatocellular cancerLiver diseaseAnimal modelsDiet-induced mouse modelGene signatureHigh-fat dietSimilar histological phenotypesAd libitum consumptionProgressive fibrosisLDL cholesterolChow dietMice fedInsulin resistanceFat dietClinical endpointsHuman NAFLDObesogenic dietPreclinical modelsMouse model
2005
A Phase I Clinical Trial of the Sequential Combination of Irinotecan Followed by Flavopiridol
Shah MA, Kortmansky J, Motwani M, Drobnjak M, Gonen M, Yi S, Weyerbacher A, Cordon-Cardo C, Lefkowitz R, Brenner B, O'Reilly E, Saltz L, Tong W, Kelsen DP, Schwartz GK. A Phase I Clinical Trial of the Sequential Combination of Irinotecan Followed by Flavopiridol. Clinical Cancer Research 2005, 11: 3836-3845. PMID: 15897584, DOI: 10.1158/1078-0432.ccr-04-2651.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBilirubinCamptothecinCell Cycle ProteinsCyclin-Dependent Kinase Inhibitor p21Drug Administration ScheduleDrug InteractionsFemaleFlavonoidsHumansIntracellular Signaling Peptides and ProteinsIrinotecanMaleMaximum Tolerated DoseMiddle AgedNeoplasmsPiperidinesTreatment OutcomeTumor Suppressor Protein p53ConceptsCombination therapyCycle 1 dose-limiting toxicitiesPhase I clinical trialDose-limiting diarrheaPhase II dosePosttreatment tumor biopsiesSignificant pharmacokinetic interactionsAdvanced solid tumorsDose-limiting toxicityPhase I trialBaseline serum bilirubinColorectal cancer xenograftsWild-type p53 tumorsMumol/LBaseline bilirubinFlavopiridol concentrationsStable diseasePartial responseI trialPharmacokinetic interactionsSerum bilirubinDifferentiation-related gene-1Responsive diseaseHepatocellular cancerCancer xenografts
2004
Liver transplantation for hepatocellular cancer: The impact of the MELD allocation policy
Wiesner RH, Freeman RB, Mulligan DC. Liver transplantation for hepatocellular cancer: The impact of the MELD allocation policy. Gastroenterology 2004, 127: s261-s267. PMID: 15508092, DOI: 10.1053/j.gastro.2004.09.040.Peer-Reviewed Original ResearchConceptsNumber of patientsHepatocellular cancerHCC patientsWaiting listLiver transplantationDeceased donorsExcellent long-term survivalPost-MELD eraAdvanced stage diseaseLiver transplant candidatesLong-term survivalHigh mortality rateProgression of HCCHCC recipientsPosttransplant survivalStage diseaseTransplant candidatesUnited NetworkDonor organsLower incidenceMortality ratePatientsAdvanced stageEarly assessmentTransplantation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply